Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NANOTAM

Financiado

Cerrado

Development and Evaluation of Nanomedicines for Cancer Treatment through Immunom...

Development and Evaluation of Nanomedicines for Cancer Treatment through Immunomodulation Targeting Tumor Associated Macrophages This project is focused on the development of novel nanomedicines effective in targeting the immunosuppressive, pro-tumoural, Tumour-Associated Macrophages (TAM) with the aim to manipulate the host’s immune system and improve anti... ver más

19/05/2017

HUMANITAS MIRASOLE...

168K€

Presupuesto del proyecto: 168K€

Líder del proyecto

HUMANITAS MIRASOLE SPA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-05-19

MSCA-IF-2014-EF: Marie Skłodowska-Curie Individual F...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

HUMANITAS MIRASOLE SPA

168.28K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BraINstorm Engineered nanocarriers for simultaneous anticancer immune r... 166K€ Cerrado

RTI2018-101309-B-C21 SINTESIS Y CARACTERIZACION DE NANOGHOSTS COMO SISTEMAS NOVED... 154K€ Cerrado

CellularNanoMachines Development of Stimuli Responsive Nanoparticle carrying T ly... 241K€ Cerrado

NANOTHER Integration of Novel Nanoparticle based Technology for Thera... 12M€ Cerrado

PDC2021-120929-I00 ESTUDIO DE PRUEBA DE CONCEPTO DE UNA NUEVA NANOTERAPIA ONCOL... 150K€ Cerrado

FJC2020-044220-I Re-educating tumor associated macrophages with nanoparticle... 53K€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2015-05-06
Fecha Fin: 2017-05-19

Líder del proyecto

HUMANITAS MIRASOLE SPA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 168K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This project is focused on the development of novel nanomedicines effective in targeting the immunosuppressive, pro-tumoural, Tumour-Associated Macrophages (TAM) with the aim to manipulate the host’s immune system and improve anti-tumour responses. In most patients, chronic inflammation and immune suppression are the dominant effects in the tumour microenvironment. The infiltration of TAM in tumour tissues has been shown to support tumour growth, invasion and metastasis. Indeed, high density of TAM in tumours is correlated with resistance to therapies and poor prognosis. These findings establish TAM as promising targets of future anti-tumour therapies. Here, we aim to design a series of Therapeutic Nanostructures (TNs), containing immunomodulatory or chemotherapeutic compounds, and conveniently functionalized, in order to target and re-educate or kill the TAM. These novel TNs will be composed of biodegradable polysaccharides, i.e. chitosan (CS) or hyaluronic acid (HA), and will be functionalized, with the aim to develop a series of targeting strategies to optimally reach TAM in vivo. These strategies involve the chemical linking of: (i) mannose residues expected to direct the TNs to the mannose receptors, highly expressed on the surface of TAM or (ii) the tumour lymphatic-specific peptide (LyP-1), known to have affinity towards NRP1 on TAM. The nanomedicines (TNs) will be loaded with pharmacological activators of TLR7 aimed to re-educate TAM into immunostimulatory anti-tumour macrophages. In the event that re-polarization of TAM is not satisfactory, or its effect is not long lasting in vivo, TNs will be loaded with chemotherapeutic drugs able to kill TAM. The TNs will be tested in vitro and in vivo to verify their effectiveness in switching back the pro-tumoural properties of TAM and their effect on tumour growth. We expect that this approach will enable greater progress in the treatment of tumours and ultimately lead to improved outcomes for cancer patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores